|1.||Baumgart, Joachim: 9 articles (04/2014 - 02/2003)|
|2.||Pichlmeier, Uwe: 5 articles (09/2011 - 02/2003)|
|3.||Zecca, Marco: 3 articles (01/2016 - 07/2012)|
|4.||Wachowiak, Jacek: 3 articles (01/2016 - 05/2007)|
|5.||Nagler, A: 3 articles (12/2015 - 02/2006)|
|6.||Shimoni, A: 3 articles (12/2015 - 02/2006)|
|7.||Andreesen, R: 3 articles (04/2015 - 04/2007)|
|8.||Kröger, Nicolaus: 3 articles (04/2014 - 07/2010)|
|9.||Mylius, Heidrun A: 3 articles (09/2011 - 07/2007)|
|10.||Giebel, Sebastian: 3 articles (09/2011 - 01/2006)|
|1.||Melanoma (Melanoma, Malignant)
01/01/2003 - "Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials."
02/01/2003 - "In conclusion, intravenous treosulfan treatment does not induce objective response rates when used as a second-line treatment of metastatic malignant melanoma."
01/01/2003 - "A total of 31 patients with stage IV melanoma were included and treated second-line with 8 g/m2 i.v. treosulfan. "
04/01/1999 - "Therefore, we conclude that treosulfan was well tolerated in this small series of patients and seems to be a promising alkylating cytostatic for the treatment of metastatic melanoma. "
04/01/1999 - "Three cell lines and eight of the 10 tested tumour cells isolated from melanoma metasteses showed tumour growth inhibition >50% after incubation with treosulfan. "
01/01/2015 - "Treosulfan is at least partially effective by triggering apoptosis of tumor cells. "
05/01/2009 - "Seventy-two hours after injection of treosulfan the ADC values in the viable parts of the tumor of mice treated with the high dose of treosulfan further increased and the tumor volume in the high-dose group was now significantly lower than in the low-dose group. "
05/01/2009 - "At 24 hours after treosulfan injection, a significantly higher increase in ADC in the viable parts of the tumor could be observed in tumors of mice that had been injected with the higher dose of treosulfan compared with mice injected with the lower dose treosulfan, whereas no significant volumetric differences between the 2 different doses could be observed. "
05/01/2009 - "T1- and T2-weighted images before administration of treosulfan showed viable tumor tissue with small necrotic areas. "
06/01/2008 - "In mice, treosulfan suppressed tumor growth at dosages of 2,500 and 3,000 mg/kg. Pharmacokinetic exposures of treosulfan in mice were similar to previous reports in human patients. "
|3.||Renal Cell Carcinoma (Grawitz Tumor)
05/01/1998 - "These results reveal the remarkable antitumor efficacy of treosulfan towards human renal-cell carcinomas, especially under in vivo conditions. "
05/01/1998 - "In the xenografted renal-cell carcinoma KTCTL-1M, treosulfan administered at the highest dose level (1 x 3,500 mg/kg) even effected a complete remission lasting for more than three weeks in all animals treated with this dose. "
07/01/1998 - "These results are encouraging and a phase II study analyzing the efficacy of treosulfan in patients with advanced renal cell carcinoma has been initiated in our institution."
03/01/1999 - "We performed a small clinical phase II study using Treosulfan as a monotherapy in the treatment of metastatic renal cell carcinoma. "
07/01/1998 - "The following study analyzes the in vitro toxicity of treosulfan on spheroids of 8 primary cultures of renal cell carcinoma cells. "
|4.||Hematologic Neoplasms (Hematological Malignancy)
08/01/2012 - "We conducted this prospective study in adult patients with various hematological malignancies in order to evaluate the toxicity and efficacy of treosulfan-based conditioning, followed by allo-HSCT from 10/10 HLA-identical unrelated donors. "
08/01/2012 - "Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor."
12/01/2011 - "Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party."
01/01/2016 - "Treosulfan based conditioning is a safe and effective approach for children with hematological malignancies, including and importantly for infants and those patients undergoing second or later transplantation. "
03/01/2013 - "Recently, treosulfan has been investigated for the treatment of hematologic malignancies in combination with the same second agents before hematopoietic stem cell transplantation. "
|5.||Ovarian Neoplasms (Ovarian Cancer)
12/01/2015 - "Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study."
12/01/2015 - "In predominantly elderly and heavily pre-treated patients with recurrent ovarian cancer, treosulfan featured a clinical relevant efficacy and well-manageable, mostly hematological, toxicity, which resulted in a positive therapeutic index."
12/01/2015 - "Two hundred and forty-eight ovarian cancer patients in 57 Centers, who received treosulfan mainly either i.v. (5,000-8,000 mg/m(2) d1, q21d or q28d) or p.o. "
08/01/2012 - "A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis."
07/01/2007 - "Treosulfan (L-threitol-1,4-bis(methanesulfonate)) is a bifunctional alkylating agent with a favorable profile of side effects, approved for the treatment of ovarian cancer. "
|4.||Adenosine Triphosphate (ATP)
|10.||Cyclooxygenase 2 (Cyclooxygenase-2)
|1.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|4.||Heterologous Transplantation (Xenotransplantation)